Certara Inc. (CERT) News
Filter CERT News Items
CERT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CERT News Highlights
- CERT's 30 day story count now stands at 2.
- Over the past 22 days, the trend for CERT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, CMC and DE are the most mentioned tickers in articles about CERT.
Latest CERT News From Around the Web
Below are the latest news stories about CERTARA INC that investors may wish to consider to help them evaluate CERT as an investment opportunity.
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel TherapiesCombined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development.PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Together, Certa |
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & developmentSimcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapiesPRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex novel and generic small molecule medicines quickly and cost effective |
Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call TranscriptCertara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript November 8, 2023 Certara, Inc. reports earnings inline with expectations. Reported EPS is $0.11 EPS, expectations were $0.11. Operator: Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being […] |
Q3 2023 Certara Inc Earnings CallQ3 2023 Certara Inc Earnings Call |
Certara, Inc. (CERT) Q3 Earnings Meet EstimatesCertara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Certara Reports Third Quarter 2023 Financial ResultsReiterates Full Year 2023 Financial GuidancePRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: Revenue was $85.6 million, compared to $84.7 million in the third quarter of 2022, representing growth of 1% over the third quarter of 2022. Broad based recovery in services bookings during the quarter. Net loss was $49.0 million, comp |
Top 12 Medical AI CompaniesIn this article, we will take a look at the top 12 medical AI companies. To see more such companies, go directly to Top 5 Medical AI Companies. The healthcare and medical industry is one of the biggest beneficiaries of the AI boom. Over the past few years and months there has been a surge in […] |
Are Options Traders Betting on a Big Move in Certara (CERT) Stock?Investors need to pay close attention to Certara (CERT) stock based on the movements in the options market lately. |
Are Certara, Inc.'s (NASDAQ:CERT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?Certara (NASDAQ:CERT) has had a rough three months with its share price down 29%. However, the company's fundamentals... |
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment ConferencePRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certar |